Enliven Therapeutics announced FDA alignment on the final design of its pivotal Phase 3 ENABLE-2 trial for relcobatinib, targeting chronic myeloid leukemia (CML). The company plans to initiate the trial before the end of 2026. Relcobatinib shows promise as a best-in-class therapy with strong clinical and preclinical data supporting its efficacy and selectivity. Enliven reported a net loss of $27.7 million for Q3 2026 but holds $884 million in cash and equivalents, providing financial stability through 2030.
Enliven Therapeutics Q3 2026 results and update provide context for health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Nov 06, 2026 04:11 WIB: out of 150 priced US health stocks, 16 rose and 134 fell. Notable movers include NTRA at USD 299.83 with a -23.32% change and 59% sell order activity, GH at USD 129.81 down 23.00%, and INO at USD 1.26 down 22.22% with 54% sell orders.
The 2026 Global Health Congress in New York gathered over 625 healthcare leaders from 25 countries to discuss innovation, equity, and investment in healthcare. The event featured 350+ startup applications in its Healthcare Shark Tank competition, cro...
Ambarella, an edge AI semiconductor company, announced its third quarter fiscal year 2027 earnings conference call will be held on November 24, 2026, at 1:30 p.m. Pacific Time. The company will release its earnings report after the market closes that...
Ademi LLP is investigating Strategic Education for potential securities fraud related to inaccurate statements about its financials and business operations, particularly in Australia. This probe follows a more than 20% decline in the company's stock ...
Corporate Insight released research identifying top financial firms leading in customer-facing AI tools, including virtual assistants and AI-powered fintech platforms. Fidelity and Voya lead in retirement plan virtual assistants, while Lively excels ...
Micron's stock dropped 17.5% in one day due to a halted $4.5 billion memory plant project in Taiwan caused by a union pay dispute demanding 15% of operating profits. This threatens production as 60% of Micron's DRAM is made in Taiwan. Despite the dro...
